Healthy Extracts Inc. (OTC: HYEX) secured $225,000 cash by issuing a $258,750 promissory note, convertible at $2.00 per share or 75% of recent low price. The infusion eases liquidity amid a 66% one‑month stock decline, but conversion could further dilute shareholders.

 

Key Highlights

  • Promissory note principal amount $258,750, net proceeds $225,000 after discount.
  • Conversion price set at the lesser of $2.00 per share or 75% of the lowest 15‑day closing bid.
  • Shares trade at approximately 0.91, down 66.1% over the past month, with a market cap of $15 million.

Healthy Extracts Inc. (OTC: HYEX) obtained $225,000 in cash through a promissory note carrying a $258,750 principal. The instrument bears a 10% interest rate earned in advance and can be turned into common shares at a floor price of $2.00 or 75% of the lowest closing bid over the fifteen days preceding conversion. Immediate capital strengthens the firm’s balance sheet while exposing investors to conversion-linked dilution risk.

New Note Mechanics

The note, issued on July 17, 2026, includes an original issue discount of $33,750, effectively lowering the net proceeds to $225,000. Interest of 10% equates to $25,875, prepaid at issuance, and monthly amortization of $36,964.28 commences on January 18, 2027 for six installments, unless the note is converted earlier. The holder, LABRYS FUND II, L.P. must retain $3,500 for legal fees and $13,500 for placement-agent compensation, both withheld from the purchase price.

The note cannot be prepaid without holder consent, and default interest rises to 16% if payments lapse. These terms embed a modest cash inflow but a structured repayment schedule that may constrain future cash flow.

Why the Timing Matters

Healthy Extracts shares sit at approximately 0.91, reflecting a 39.9% decline year‑to‑date and a sharper 66.1% slide over the last month, pushing the market cap to roughly $15 million. The 52‑week price range spans $0.81 to $3.35, highlighting considerable volatility. In this context, the fresh $225,000 injection provides needed liquidity to sustain operations and fund ongoing initiatives.

However, the conversion feature, anchored at $2.00 or a discount to recent lows, could trigger share issuance if the stock rebounds, further pressuring the already depressed price. Investors must weigh the short‑term cash benefit against the dilution potential inherent in the conversion clause.

Forward Catalyst: Conversion Window

The note becomes convertible after 180 days, placing the first conversion opportunity in early January 2027. Should the stock trade above the $2.00 floor or if a 75% low‑price trigger materializes, LABRYS FUND II may elect to swap debt for equity, altering the share count. Market participants will watch the January 18, 2027 amortization start date and any price movement leading up to the conversion window, as these events will define the ultimate impact on shareholder value.

Analysis based on the Form 8-K filed 24 July 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.